Skip to main content

Table 2 Initial treatment response to different initial afatinib doses

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Variables

All patients

Afatinib 30 mg daily

Afatinib 40 mg daily

P value

Initial response to afatinib treatment -n (%)

   

0.1661

 Complete response

2 (1%)

1 (1%)

1 (1%)

 

 Partial response

138 (77%)

75 (74%)

63 (82%)

 

 Stable disease

35 (20%)

25 (25%)

10 (13%)

 

 Progressive disease

4 (2%)

1 (1%)

3 (4%)

 

Disease control rate with afatinib treatment (%)

175 (98%)

101 (99%)

74 (96%)

0.1913

Response rate with afatinib treatment (%)

140 (78%)

76 (75%)

64 (83%)

0.1672